{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+0.02+mL", "query": { "intervention": "Placebo 0.02 mL" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 18, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+0.02+mL&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-07T17:42:33.463Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00044694", "title": "Evaluation of the Effect on Glucose Control and the Safety and Tolerability of AC2993 in Patients With Type 2 Diabetes Mellitus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetes Mellitus, Non-Insulin-Dependent" ], "interventions": [ { "name": "Placebo 0.01 mL", "type": "DRUG" }, { "name": "Placebo 0.02 mL", "type": "DRUG" }, { "name": "Placebo 0.03 mL", "type": "DRUG" }, { "name": "Placebo 0.04 mL", "type": "DRUG" }, { "name": "AC2993 2.5 mcg", "type": "DRUG" }, { "name": "AC2993 5.0 mcg", "type": "DRUG" }, { "name": "AC2993 7.5 mcg", "type": "DRUG" }, { "name": "AC2993 10.0 mcg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 156, "start_date": "2002-08", "completion_date": "2003-05", "has_results": false, "last_update_posted_date": "2015-02-20", "last_synced_at": "2026-09-07T17:42:33.463Z", "location_count": 33, "location_summary": "Birmingham, Alabama • Anaheim, California • Bellflower, California + 28 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Anaheim", "state": "California" }, { "city": "Bellflower", "state": "California" }, { "city": "Chula Vista", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00044694" }, { "nct_id": "NCT04381468", "title": "SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Alzheimer Disease" ], "interventions": [ { "name": "Pepinemab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vaccinex Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "55 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "55 Years to 85 Years" }, "enrollment_count": 50, "start_date": "2021-07-22", "completion_date": "2024-06-05", "has_results": false, "last_update_posted_date": "2024-08-22", "last_synced_at": "2026-09-07T17:42:33.463Z", "location_count": 14, "location_summary": "San Diego, California • Washington D.C., District of Columbia • Delray Beach, Florida + 11 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Delray Beach", "state": "Florida" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Lake Worth", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04381468" }, { "nct_id": "NCT03775382", "title": "Mechanisms of Impaired Brain Blood Flow With Aging", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Aging" ], "interventions": [ { "name": "Ascorbic Acid", "type": "OTHER" }, { "name": "Normal Saline", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Delaware", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "79 Years", "sex": "ALL", "summary": "18 Years to 79 Years" }, "enrollment_count": 34, "start_date": "2017-10-30", "completion_date": "2022-06-01", "has_results": false, "last_update_posted_date": "2023-05-10", "last_synced_at": "2026-09-07T17:42:33.463Z", "location_count": 1, "location_summary": "Newark, Delaware", "locations": [ { "city": "Newark", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT03775382" }, { "nct_id": "NCT04715022", "title": "Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hypertension", "Cardiovascular Diseases" ], "interventions": [ { "name": "Ascorbic acid solution (American Regent Laboratories Inc.)", "type": "DRUG" }, { "name": "Saline", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Kansas Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "35 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "35 Years to 65 Years" }, "enrollment_count": 23, "start_date": "2021-06-17", "completion_date": "2027-08-01", "has_results": false, "last_update_posted_date": "2025-06-08", "last_synced_at": "2026-09-07T17:42:33.463Z", "location_count": 1, "location_summary": "Kansas City, Kansas", "locations": [ { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04715022" }, { "nct_id": "NCT00039026", "title": "Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With a Sulfonylurea", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Non-Insulin-Dependent" ], "interventions": [ { "name": "AC2993", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "16 Years to 75 Years" }, "enrollment_count": 377, "start_date": "2002-02", "completion_date": "2003-08", "has_results": false, "last_update_posted_date": "2015-02-24", "last_synced_at": "2026-09-07T17:42:33.463Z", "location_count": 126, "location_summary": "Anniston, Alabama • Birmingham, Alabama • Eclectic, Alabama + 99 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Eclectic", "state": "Alabama" }, { "city": "Haleyville", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT00039026" }, { "nct_id": "NCT03844412", "title": "Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Vestibulodynia", "Temporomandibular Disorder", "Fibromyalgia Syndrome", "Irritable Bowel Syndrome", "Migraines", "Tension Headache", "Endometriosis", "Interstitial Cystitis", "Back Pain", "Chronic Fatigue Syndrome" ], "interventions": [ { "name": "5% lidocaine/5 mg/ml 0.02% estradiol compound cream", "type": "DRUG" }, { "name": "Nortriptyline", "type": "DRUG" }, { "name": "Placebo cream", "type": "DRUG" }, { "name": "Placebo pill", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "FEMALE", "summary": "18 Years to 50 Years · Female only" }, "enrollment_count": 209, "start_date": "2019-11-04", "completion_date": "2024-05-30", "has_results": true, "last_update_posted_date": "2026-03-19", "last_synced_at": "2026-09-07T17:42:33.463Z", "location_count": 2, "location_summary": "Los Angeles, California • Chapel Hill, North Carolina", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03844412" }, { "nct_id": "NCT02215200", "title": "ATG-GCSF in New Onset Type 1 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetes Mellitus, Type 1" ], "interventions": [ { "name": "Anti-Thymocyte Globulin (ATG)", "type": "DRUG" }, { "name": "Granulocyte colony stimulating factor (GCSF)", "type": "DRUG" }, { "name": "Placebo (for ATG)", "type": "DRUG" }, { "name": "Placebo (for GCSF)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "12 Years to 45 Years" }, "enrollment_count": 89, "start_date": "2014-12", "completion_date": "2018-08", "has_results": true, "last_update_posted_date": "2020-03-02", "last_synced_at": "2026-09-07T17:42:33.463Z", "location_count": 13, "location_summary": "San Francisco, California • Stanford, California • Aurora, Colorado + 10 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02215200" }, { "nct_id": "NCT00039013", "title": "Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With Metformin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "AC2993", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "16 Years to 75 Years" }, "enrollment_count": 336, "start_date": "2002-03", "completion_date": "2003-06", "has_results": false, "last_update_posted_date": "2015-02-24", "last_synced_at": "2026-09-07T17:42:33.463Z", "location_count": 129, "location_summary": "Anniston, Alabama • Birmingham, Alabama • Eclectic, Alabama + 99 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Eclectic", "state": "Alabama" }, { "city": "Haleyville", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT00039013" }, { "nct_id": "NCT04832009", "title": "Reversing Glucose and Lipid-mediated Vascular Dysfunction", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Blood Pressure", "Hypertension" ], "interventions": [ { "name": "Dextrose 20 % in 500 ML Injection", "type": "DRUG" }, { "name": "Intralipid", "type": "DRUG" }, { "name": "Saline", "type": "DRUG" }, { "name": "Ascorbic acid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Kansas Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "79 Years", "sex": "ALL", "summary": "18 Years to 79 Years" }, "enrollment_count": 46, "start_date": "2022-05-09", "completion_date": "2027-08-01", "has_results": false, "last_update_posted_date": "2025-06-05", "last_synced_at": "2026-09-07T17:42:33.463Z", "location_count": 1, "location_summary": "Kansas City, Kansas", "locations": [ { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04832009" }, { "nct_id": "NCT03005717", "title": "Study to Evaluate the Safety and Efficacy of LIPO-202 for the Reduction of Submental Subcutaneous Fat", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Submental Fat" ], "interventions": [ { "name": "LIPO-202", "type": "DRUG" }, { "name": "Placebo for LIPO-202", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Neothetics, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 162, "start_date": "2016-12-22", "completion_date": "2017-06-02", "has_results": false, "last_update_posted_date": "2017-10-20", "last_synced_at": "2026-09-07T17:42:33.463Z", "location_count": 11, "location_summary": "Beverly Hills, California • Manhattan Beach, California • Greenwood Village, Colorado + 8 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Manhattan Beach", "state": "California" }, { "city": "Greenwood Village", "state": "Colorado" }, { "city": "Coral Gables", "state": "Florida" }, { "city": "Warren", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03005717" } ] }